Literature DB >> 18722676

Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience.

Lorenzo Maggi1, Francesca Andreetta, Carlo Antozzi, Fulvio Baggi, Pia Bernasconi, Paola Cavalcante, Ferdinando Cornelio, Giuseppe Muscolino, Lorenzo Novellino, Renato Mantegazza.   

Abstract

We studied 197 patients with thymoma-associated myasthenia gravis (T-MG) to identify variables that can influence the natural history of the disease and the therapeutical approaches. Multivariate analysis showed that neither clinical nor pathological variables were associated with a better chance to reach complete stable remission. The video-assisted thoracoscopic extended thymectomy (VATET) was not significantly correlated with a lower chance of achieving complete stable remission compared with the classical transsternal approach (T-3b) (p=0.1090). Thymoma recurrence was not correlated with surgery by VATET or T-3b. VATET was safe and reliable for removal of thymoma. The low chance of achieving remission (9.64%) in T-MG underlines the importance of an early diagnosis as well as the need for more aggressive therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18722676     DOI: 10.1016/j.jneuroim.2008.07.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

1.  Thymoma-associated exfoliative dermatitis with post-thymectomy myasthenia gravis in a cat.

Authors:  Ameet Singh; Sarah E Boston; Roberto Poma
Journal:  Can Vet J       Date:  2010-07       Impact factor: 1.008

Review 2.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

3.  Clinical outcome and predictive factors of irradiation-associated myasthenia gravis exacerbation in thymomatous patients.

Authors:  Yan Li; Pei Chen; Li Ding; Chuanming Luo; Haiyan Wang; Zhenguang Chen; Chunhua Su; Huiyu Feng; Xin Huang; Weixiong Xia; Weibin Liu
Journal:  Neurol Sci       Date:  2015-07-26       Impact factor: 3.307

4.  Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.

Authors:  H-W Yang; P Lei; Y-C Xie; Z-L Han; D Li; S-H Wang; Z-L Sun
Journal:  Cancer Gene Ther       Date:  2017-04-21       Impact factor: 5.987

5.  [Clinical and paraclinical profile of autoimmune myasthenia gravis in Ouagadougou, Burkina Faso].

Authors:  Djingri Labodi Lompo; Nagaonlé Éric Some; Adja Mariam Ouedraogo; Rodrigue P Yonli; Ousséini Diallo; Christian Napon; Athanase Millogo; Jean Kabore
Journal:  Med Trop Sante Int       Date:  2021-11-11

6.  Current and emerging therapies for the treatment of myasthenia gravis.

Authors:  Renato Mantegazza; Silvia Bonanno; Giorgia Camera; Carlo Antozzi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-03-22       Impact factor: 2.570

Review 7.  Myasthenia gravis associated with invasive malignant thymoma: two case reports and a review of the literature.

Authors:  Said R Beydoun; Hui Gong; Nazely Ashikian; Richard Alan Rison
Journal:  J Med Case Rep       Date:  2014-10-13

Review 8.  When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.

Authors:  Renato Mantegazza; Carlo Antozzi
Journal:  Ther Adv Neurol Disord       Date:  2018-01-18       Impact factor: 6.570

9.  Surgical approaches for stage I and II thymoma-associated myasthenia gravis: feasibility of complete video-assisted thoracoscopic surgery (VATS) thymectomy in comparison with trans-sternal resection.

Authors:  Zhicheng He; Quan Zhu; Wei Wen; Liang Chen; Hai Xu; Hai Li
Journal:  J Biomed Res       Date:  2012-11-30

10.  HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications.

Authors:  S Janik; A I Schiefer; C Bekos; P Hacker; T Haider; J Moser; W Klepetko; L Müllauer; H J Ankersmit; B Moser
Journal:  Sci Rep       Date:  2016-04-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.